{"Name":"BiPar Sciences","perma":"bipar-sciences","BasicInfo":{"funded":"2002-01-01","isClosed":false,"closed":null,"short":"BiPar Sciences is a pharmacological company developing PARP inhibitors as cancer therapies."},"FundingRounds":[{"funding_type":"venture","series":"c","announcedDate":"2009-01-12","moneyRaised":20000000},{"funding_type":"venture","series":"b","announcedDate":"2007-02-26","moneyRaised":35000000},{"funding_type":"debt_financing","series":null,"announcedDate":"2006-06-14","moneyRaised":5000000},{"funding_type":"venture","series":"a","announcedDate":"2004-12-20","moneyRaised":13000000}],"Acquisitions":[],"AcquiredBy":{"price":500000000,"paymentType":null,"announcedDate":"2009-04-15","completedDate":null,"acquisitionType":"Acquisition","acquirer":"Sanofi Aventis"},"IPO":null,"Investments":[],"Products":[{"name":"BSI-201","perma":"bsi-201","launch":null,"close":null,"description":"BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation.","newsCount":1,"news":[{"title":"Visible Raises $6M, Vulcan Goes Deep with BiPar, IdeaScale Serves White House, & More Seattle-Area Deals News | Xconomy","date":"2009-05-26"}]}],"CurrentTeam":[{"title":"Vice President, Regulatory Affairs","started":null,"ended":null,"firstName":"Deborah A.","lastName":"Thomas, Ph.D."},{"title":"Vice President, Clinical Development","started":null,"ended":null,"firstName":"Charles","lastName":"Bradley, Ph.D."},{"title":"Chief Financial Officer","started":null,"ended":null,"firstName":"John","lastName":"Schembri"},{"title":"Executive Vice President, Development","started":null,"ended":null,"firstName":"Barry","lastName":"Sherman, M.D."}],"PastTeam":[{"title":"Founder, President & CEO","started":null,"ended":null,"firstName":"Tom","lastName":"White"},{"title":"President / CEO / Chairman","started":null,"ended":"2009-01-01","firstName":"Hoyoung","lastName":"Huh"},{"title":"Corporate Development and Marketing","started":null,"ended":null,"firstName":"Sunil","lastName":"Patel"}]}
